MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
5.11
-0.45
-8.09%
Opening 10:43 12/08 EST
OPEN
5.87
PREV CLOSE
5.56
HIGH
6.14
LOW
4.985
VOLUME
3.51M
TURNOVER
--
52 WEEK HIGH
6.14
52 WEEK LOW
1.340
MARKET CAP
171.58M
P/E (TTM)
-6.6004
1D
5D
1M
3M
1Y
5Y
1D
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026
NASDAQ · 12h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 13h ago
Immix Biopharma Announces Positive Phase 2 Trial Results
TipRanks · 13h ago
Immix Biopharma 19.12M share Spot Secondary priced at $5.10
TipRanks · 13h ago
Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for AL Amyloidosis
Reuters · 13h ago
Weekly Report: what happened at IMMX last week (1201-1205)?
Weekly Report · 14h ago
Reported Sunday, Immix Biopharma Says NXC-201 Shows 75% CR By Independent Review, With MRD Negativity Potentially Raising CR To 95%
Benzinga · 17h ago
Immix Biopharma prices $100M equity raise via common stock and warrant offering
Seeking Alpha · 18h ago
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.